Form 4: CareDx Director Hannah Valantine Reports Acquisition of Restricted Stock Units

CareDx, Inc. Director Hannah Valantine reported the acquisition of 12,103 restricted stock units, increasing her beneficial ownership to 49,564 shares.

Summary

• Hannah Valantine, a Director of CareDx, Inc. (CDNA), acquired 12,103 shares of common stock in the form of restricted stock units (RSUs) on June 13, 2025.
• The acquisition was reported at a price of $0.00 per share, indicating a grant rather than a purchase.
• Following this transaction, Ms. Valantine's total beneficial ownership of CareDx common stock increased to 49,564 shares.
• The acquired restricted stock units are scheduled to vest in one installment on the earlier of (i) June 13, 2026, or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is a positive sign of alignment between management and shareholder interests, as it ties compensation to future company performance. While not directly indicative of financial performance, it reflects confidence and standard governance practices.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, as the value of the compensation is tied to the company's future stock performance.
• The increase in beneficial ownership by a director can be viewed as a positive signal of confidence in the company's long-term prospects.

Future Outlook

The acquired restricted stock units are forward-looking compensation, with vesting contingent on future dates, specifically the earlier of June 13, 2026, or the day prior to the first annual meeting of stockholders after June 13, 2025.

Industry Context

The grant of restricted stock units to directors is a common and standard practice in publicly traded companies across various industries, serving as a form of equity-based compensation to attract and retain talent while aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation practice for publicly traded companies, comparable to similar equity compensation plans observed at companies like Illumina, Inc. (ILMN) or Exact Sciences Corp. (EXAS) in the life sciences and diagnostics sector, which often use RSUs to incentivize and retain key personnel and board members.

Related Party Transactions

• The acquisition of restricted stock units by a director from the company constitutes a related party transaction, which is a standard form of compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value, potentially leading to more favorable decision-making for the company's stock performance.

Next Steps

• Vesting of the 12,103 restricted stock units on the earlier of June 13, 2026, or the day prior to the first annual meeting of stockholders after June 13, 2025.

Key Dates

Recommendation

Keywords

CareDx, CDNA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Stock Grant, Hannah Valantine